中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.028 seconds)

    CMV NEUTRALIZING ANTIGEN BINDING PROTEINS
    1.
    发明申请
    CMV NEUTRALIZING ANTIGEN BINDING PROTEINS 有权
    CMV中和抗原结合蛋白

    公开(公告)号：US20160130327A1

    公开(公告)日：2016-05-12

    申请号：US14897374

    申请日：2014-06-09

    Applicant: Tong-Ming FU ,  Dai WANG ,  Zhiqiang AN

    Inventor： Tong-Ming Fu ,  Dai Wang ,  Zhiqiang An

    IPC: C07K16/08

    CPC classification number: C07K16/088 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q1/70

    Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.

    Abstract translation: 本发明涉及特异性结合并优选中和人巨细胞病毒（CMV）的抗原结合蛋白，包括但不限于单克隆抗体及其抗原结合片段。 本发明还包括已经人源化的抗原结合蛋白。 本发明的抗原结合蛋白可用作治疗和/或预防有需要的患者的CMV感染的治疗剂。

    Polynucleotide vaccines expressing codon optimized HIV-1 Pol and modified HIV-1 Pol
    4.
    发明申请
    Polynucleotide vaccines expressing codon optimized HIV-1 Pol and modified HIV-1 Pol 审中-公开
    表达密码子优化的HIV-1 Pol和修饰的HIV-1 Pol的多核苷酸疫苗

    公开(公告)号：US20060148750A1

    公开(公告)日：2006-07-06

    申请号：US11345127

    申请日：2006-02-01

    Applicant: John Shiver ,  Helen Perry ,  Danilo Casimiro ,  Tong-Ming Fu

    Inventor： John Shiver ,  Helen Perry ,  Danilo Casimiro ,  Tong-Ming Fu

    IPC: A61K48/00

    CPC classification number: C07K14/005 ,  A61K2039/53 ,  C07H21/02 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2800/22

    Abstract: Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The pol-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and preferably express inactivated versions of the HIV Pol protein devoid of protease, reverse transcriptase activity, RNase H activity and integrase activity, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Pol and codon optimized inactive derivatives of optimized HIV-1 Pol, including DNA molecules which encode inactive Pol proteins which comprise an amino terminal leader peptide.

    Abstract translation: 公开了包含HIV Pol DNA疫苗的药物组合物以及这些DNA疫苗的生产和使用。 将本发明的基于pol的DNA疫苗直接施用于活的脊椎动物组织，优选人，并且优选表达不含蛋白酶的HIV Pol蛋白，逆转录酶活性，RNase H活性和整合酶活性的失活形式，诱导细胞免疫 具体承认人体免疫缺陷病毒-1（HIV-1）的反应。 构成这些DNA疫苗的开放阅读框架的DNA分子是编码经优化的HIV-1 Pol的密码子优化的HIV-1 Pol和密码子优化的非活性衍生物的合成DNA分子，其包括编码无效Pol蛋白的DNA分子，其包含氨基末端引物 肽。

    Method of inducing an enhanced immune response against hiv
    6.
    发明申请
    Method of inducing an enhanced immune response against hiv 审中-公开
    诱导针对HIV的增强的免疫应答的方法

    公开(公告)号：US20060165664A1

    公开(公告)日：2006-07-27

    申请号：US10507237

    申请日：2003-03-12

    Applicant: Emilio Emini ,  John Shiver ,  Danilo Casimiro ,  Andrew Bett ,  Xiaoping Liang ,  Tong-Ming Fu

    Inventor： Emilio Emini ,  John Shiver ,  Danilo Casimiro ,  Andrew Bett ,  Xiaoping Liang ,  Tong-Ming Fu

    IPC: A61K48/00 ,  A61K39/21

    CPC classification number: C12N15/86 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5256 ,  A61K2039/545 ,  C07K14/005 ,  C12N2710/10343 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16234 ,  C12N2740/16322 ,  C12N2740/16334 ,  C12N2830/42

    Abstract: An efficient means of inducing an immune response against human immunodeficiency virus (HIV) utilizing specific prime-boost regimes is disclosed. The specific prime-boost regimes employ a heterologous prime-boost protocol employing recombinant adenoviral vectors of alternative and distinct serotypes comprising exogenous genetic material encoding a common HIV antigen. Vaccines administered into living vertebrate tissue in accordance with the disclosed regimes, preferably a mammalian host, such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 antigen (e.g., Gag), inducing a cellular immune response which specifically recognizes HIV-1. It is believed that the disclosed prime/boost regime will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

    Abstract translation: 公开了一种利用特定初始 - 加强方案诱导针对人类免疫缺陷病毒（HIV）的免疫应答的有效手段。 特定的初始 - 加强方案采用异源初始 - 加强方案，其使用包含编码常见HIV抗原的外源遗传物质的替代和不同血清型的重组腺病毒载体。 根据所公开的方案，优选哺乳动物宿主，如商业或家畜兽医学重要的人或非人哺乳动物施用于活的脊椎动物组织中的疫苗表达HIV-1抗原（例如，Gag），诱导细胞 特异性识别HIV-1的免疫反应。 相信所公开的主要/加强方案将对先前未感染的个体提供预防优势，和/或通过减少感染个体内的病毒载量水平提供治疗效果，从而延长HIV-1感染的无症状期。

    VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF
    8.
    发明申请
    VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF 审中-公开
    各种HCMV PP65，IE1和IE2多核苷酸及其用途

    公开(公告)号：US20110136896A1

    公开(公告)日：2011-06-09

    申请号：US13056899

    申请日：2009-07-28

    Applicant: Tong-Ming Fu ,  Danilo R. Casimiro ,  Daniel C. Freed ,  Aimin Tang

    Inventor： Tong-Ming Fu ,  Danilo R. Casimiro ,  Daniel C. Freed ,  Aimin Tang

    IPC: A61K31/7088 ,  C07H21/04 ,  C07K14/005 ,  C12N15/63 ,  C12P21/06

    CPC classification number: C07K14/005 ,  C12N2710/16122

    Abstract: The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified forms of the variant HCMV pp65, IE1, and IE2 proteins described herein, and fusion proteins. The variant HCMV proteins, and fusion proteins thereof, are useful as vaccines for the protection from and/or treatment of HCMV infection. Said vaccines are useful as a monotherapy or a part of a therapeutic regime, said regime comprising administration of a second vaccine such as a polynucleotide, cell-based, protein or peptide-based vaccine.

    Abstract translation: 本发明涉及通过提供编码变体HCMV pp65，IE1和IE2蛋白的多核苷酸及其融合蛋白来引发或增强细胞介导的HCMV感染免疫的组合物和方法。 本发明还提供重组载体，包括但不限于腺病毒和包含所述多核苷酸的质粒载体和包含所述重组载体的宿主细胞。 本文还提供了本文所述的变体HCMV pp65，IE1和IE2蛋白的纯化形式，以及融合蛋白。 变体HCMV蛋白及其融合蛋白可用作用于保护和/或治疗HCMV感染的疫苗。 所述疫苗可用作单一疗法或治疗方案的一部分，所述方案包括施用第二种疫苗，例如多核苷酸，基于细胞的，蛋白质或基于肽的疫苗。

    Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
    9.
    发明申请
    Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef 审中-公开
    表达密码子优化的HIV-1 Nef和修饰的HIV-1 Nef的多核苷酸疫苗

    公开(公告)号：US20050215508A1

    公开(公告)日：2005-09-29

    申请号：US11081244

    申请日：2005-03-16

    Applicant: John Shiver ,  Xiaoping Liang ,  Tong-Ming Fu

    Inventor： John Shiver ,  Xiaoping Liang ,  Tong-Ming Fu

    IPC: A61K48/00 ,  C07K14/16

    CPC classification number: C07K14/005 ,  A61K2039/53 ,  C12N2740/16322

    Abstract: Pharmaceutical compositions which comprise HIV Nef DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The nef-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and express the HIV Nef protein or biologically relevant portions thereof, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef modifications comprising amino terminal leader peptides, removal of the amino terminal myristylation site, and/or modification of the Nef dileucine motif. These modifications may effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4.

    Abstract translation: 公开了包含HIV Nef DNA疫苗的药物组合物以及这些DNA疫苗的生产和使用。 将本发明的基于nef的DNA疫苗直接施用于活的脊椎动物组织，优选人，并且表达HIV Nef蛋白或其生物相关部分，诱导特异性识别人免疫缺陷病毒-1（HIV-1 ）。 构成这些DNA疫苗的开放阅读框架的DNA分子是编码密码子优化的HIV-1 Nef和优化的HIV-1 Nef的衍生物的合成DNA分子，包括包含氨基末端前导肽的nef修饰，氨基末端的肉豆蔻酰化位点的去除， 和/或Nef二氨基酸基序的修饰。 这些修饰可能会影响Nef的野生型特征，如主要病毒的肉豆蔻酰化和下调。

    Conditional replicating cytomegalovirus as a vaccine for CMV
    10.
    发明授权
    Conditional replicating cytomegalovirus as a vaccine for CMV 有权
    条件复制巨细胞病毒作为CMV疫苗

    公开(公告)号：US09546355B2

    公开(公告)日：2017-01-17

    申请号：US14343637

    申请日：2012-09-04

    Applicant: Tong-Ming Fu ,  Dai Wang ,  Muneeswara Babu Medi

    Inventor： Tong-Ming Fu ,  Dai Wang ,  Muneeswara Babu Medi

    IPC: C12N7/00 ,  A61K39/12 ,  A61K39/00

    CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/55505 ,  A61K2039/55577 ,  C12N2710/16134

    Abstract: The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.

    Abstract translation: 本发明涉及使用有条件复制缺陷的遗传修饰的CMV诱导对巨细胞病毒（CMV）的免疫应答的方法。 本发明的方法可用于治疗和/或预防原发性CMV感染，由于潜在CMV的再活化引起的感染和先前已经遇到的不同CMV株的超感染。 本发明还涉及重组改变以​​允许外部控制病毒复制的复制缺陷型CMV。 包含复制缺陷型CMV的组合物也包括在本发明中。

Patent Agency Ranking